WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='3.227.251.94'

WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SHOW FULL COLUMNS FROM `wp_clean_up_optimizer_ip_locations`

MMED.NE – Shroom Investor 🍄

MMED.NE

Mind Medicine (MindMed) Inc.

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body NEW YORK, Jan. 12, 2021 -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced an innovative randomi... Read More...

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand

Bolsters Cash on Hand to CAD $183.0m (USD $144.4m)NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, Jan. 7, 2021 -- Mind Medicine (MindMed) Inc. (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ) ("MindMed") is pleased to announce that it has closed its previously announced bought deal short for... Read More...

Four Top Psychedelic Stock Picks for 2021

The Top Companies Addressing Mental Health CrisisATLANTA, Jan. 04, 2021 -- 2020 was a banner year for investors in psychedelic companies as investors in Mind Medicine (MindMed) Inc. (OTCQB: MMEDF), 20/20 Global, Inc. (OTC: TWGL), Compass Pathways (NASDAQ: CMPS), and Numinus Wellness Inc. (OTC: LKYSF) saw their money triple and even quadru... Read More...

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

NEW YORK, Nov. 24, 2020 -- MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company r... Read More...

MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities

Project Lucy Submits Pre-IND Briefing Package to the FDA; Agrees Q1 Interim Analysis of Swiss Phase 2a Trial of LSD Assisted Therapy for Anxiety DisordersNEW YORK and BASEL, Switzerland, Nov. 16, 2020 -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, has received a positive response on its ... Read More...

MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD

Data to Support MindMed's Project Lucy in Preparing Phase 2b Trial for Anxiety DisordersNEW YORK, Nov. 2, 2020 -- MindMed (NEO: MMED, OTCQB: MMEDF), the leading psychedelic medicine biotech company in partnership with University Hospital Basel's Liechti Lab announces the completion and publication of a Phase 1 study on the acute dose depe... Read More...

MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines

Post-Financing Cash Reserves of CAD $50.1m (USD $37.8m) to Enable Continued Advancement of Diverse and Growing Clinical Trial Pipeline of PsychedelicsNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, Oct. 30, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) ("MindMed" o... Read More...

MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines

MindMed To Provide Funding for Psychedelic Medicine Research Training Program at NYU Langone Health and NYU Grossman School of Medicine NEW YORK, Oct. 5, 2020 -- MindMed (NEO: MMED) (OTCQB: MMEDF), the leading psychedelic medicine biotech company, on the heels of filing a NASDAQ uplisting application, today announced a funding commitment ... Read More...

MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor

NEW YORK, Sept. 21, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market ("NASDAQ").Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))As ... Read More...

MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy

Applauds Health Canada's Approval Of Psilocybin Compassionate Access For PatientsNEW YORK, Aug. 6, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Pr... Read More...

MindMed Completes Dosing 18-MC Phase 1 Study

Company, seeing early success, will advance preparations for Phase 2a clinical trial in opioid addictionNEW YORK, July 28, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has concluded dosing in a Phase 1 Single Ascending Dose (SAD) study of 18-MC. The dosing of 18-MC was well... Read More...

MindMed Closes Upsized Financing of $13.2m to Advance UHB Liechti Lab Collaboration for Next-Gen Psychedelic Inspired Medicines

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO , May 26, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) ("MindMed" or the "Company") is pleased to announce that it has closed its previously announced bought deal short form prospectus offering, including the exercis... Read More...

Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips

Advances Discovered in Collaboration with University Hospital Basel's Liechti Laboratory and Aims To Enhance Therapeutic Potential of PsychedelicsNEW YORK, April 21, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), in collaboration with University Hospital Basel's Liechti Laboratory, has discovered and filed a patent applica... Read More...

MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

NEW YORK, April 16, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. 18-MC is a proprietary, orall... Read More...

MindMed Acquires Exclusive License to Eight Clinical Trials of LSD, Partners with World-Leading Psychedelic Research Laboratory at University Hospital Basel

Multi-year deal gives MindMed access to largest collection of clinical trials & knowhow for LSD psychedelic research including a Phase 2 clinical trial of LSD for the treatment of anxietyBASEL, Switzerland, April 1, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTC: MMEDF), the leading neuro-pharmaceutical company for psychedelic in... Read More...